Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Non Operating Income (2020 - 2023)

Alx Oncology Holdings' Non Operating Income history spans 4 years, with the latest figure at -$29000.0 for Q4 2023.

  • For Q4 2023, Non Operating Income fell 1350.0% year-over-year to -$29000.0; the TTM value through Dec 2023 reached $389000.0, up 1720.83%, while the annual FY2025 figure was $104000.0, 620.0% up from the prior year.
  • Non Operating Income for Q4 2023 was -$29000.0 at Alx Oncology Holdings, down from -$1000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.0 million in Q4 2021 and bottomed at -$305000.0 in Q2 2020.
  • The 4-year median for Non Operating Income is -$1500.0 (2021), against an average of $1.2 million.
  • The largest YoY upside for Non Operating Income was 6580.0% in 2023 against a maximum downside of 1350.0% in 2023.
  • A 4-year view of Non Operating Income shows it stood at $7.8 million in 2020, then soared by 41.79% to $11.0 million in 2021, then tumbled by 100.02% to -$2000.0 in 2022, then crashed by 1350.0% to -$29000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Non Operating Income are -$29000.0 (Q4 2023), -$1000.0 (Q3 2023), and $324000.0 (Q2 2023).